FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed ...
Please provide your email address to receive an email when new articles are posted on . A prior study found that a combination macitentan and tadalafil tablet increased 6-minute walk distance at 16 ...
The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study. The combination is ...
OPSYNVI ® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical ...
Two data sets from patients with severe pulmonary arterial hypertension (PAH) show the benefits of macitentan (Opsumit) monotherapy despite guidelines calling for combination therapy, even among ...
Seasons Biotechnology and several Novugen entities were hit with a patent infringement lawsuit on Aug. 28 in New Jersey District Court over their attempt to market a generic version of the pulmonary ...
Please provide your email address to receive an email when new articles are posted on . Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results